Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up.
about
Neuroinflammatory responses in diabetic retinopathyLaser, intravitreal drug application, and surgery to treat diabetic eye diseaseSustained delivery of a HIF-1 antagonist for ocular neovascularization.Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy.Proliferative diabetic retinopathy: predictive and preventive measures at hypoxia induced retinal changes.New Therapeutic Approaches in Diabetic Retinopathy.Treatment of proliferative diabetic retinopathy with anti-VEGF agents.Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF EraVisual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: the DRIVE UK studyColor vision is strongly associated with retinal thinning in multiple sclerosis.Angiogenic potential of vitreous from Proliferative Diabetic Retinopathy and Eales' Disease patients.Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy.The 5-year onset and regression of diabetic retinopathy in Chinese type 2 diabetes patients.Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.Intravitreal injection of Bevacizumab in diabetic macular edemaEvolving strategies in the management of diabetic retinopathyEffects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α.Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practiceEvidence-Based Treatment of Diabetic Retinopathy.Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathyThe Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic SubjectsTreatment of diabetic retinopathy with anti-VEGF drugs.Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathyMacular edema formation and deterioration of retinal function after intravitreal bevacizumab injection for proliferative diabetic retinopathyIntracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series.Effect of intravitreal bevacizumab (avastin) on the growing rabbit eye.Single-dose Intravitreal Bevacizumab after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: an Effective Adjunctive Treatment.Evaluation of vitreous levels of advanced glycation end products and angiogenic factors as biomarkers for severity of diabetic retinopathy.Observation of optic disc neovascularization using OCT angiography in proliferative diabetic retinopathy after intravitreal conbercept injections.Intravitreal Bevacizumab Injection Attenuates Diabetic Retinopathy in Adult Rats with Experimentally Induced Diabetes in the Early Stage.
P2860
Q26798351-1108BAD9-8364-43CE-9DA9-A6D128811B4AQ26995365-609AEF33-8FE6-4581-BA4A-5E95CD232EC8Q30560557-0680F51D-691F-4511-97CA-097583C7A810Q30979491-E0F6E955-6DC1-4E75-8208-C9FBA11752A6Q31107603-45380557-4EBC-4A09-9C52-666AA7B512E3Q33583037-0BC3DE4C-7911-42B5-9005-B897EA80EDCBQ33812021-FDFD721F-B9BC-488D-9A4F-BACCA5191D58Q33902419-64A90938-E877-4300-86E5-F5E5A962A42DQ33905676-75992C16-8519-4077-A0EC-96EE05E300FCQ34119754-D92CE27F-A4C5-448D-A2A5-7AC399C566A1Q34145469-1801849F-A235-4D63-8D23-6BF36BC9799FQ34331514-70FC50C5-1B1B-4830-9316-79BF2962855FQ34440571-2D4A16CD-CA08-40CE-BC47-3E62D45CB887Q34474545-E7477813-825A-42E4-A2F0-B59C261D6078Q34526936-807D106B-B2B7-434B-B806-84108C33C640Q34621295-8BE3B3FB-801E-4D92-8BE7-A1DE659343EDQ34987495-C1451B49-44E0-4AFF-B1B0-C83BD0EB3F80Q35061041-8133FDBA-28EE-4495-B12B-90FA7D36AE4AQ35067102-5F8D35A0-81FA-4D3F-8E2C-B38D512AD963Q35658383-AD8EEDEB-A91D-4604-9BBA-5122959C5CF0Q35886784-56B5FC38-9FF5-4A59-9EC0-6CDC35BCAA21Q36152543-9680E6ED-E18D-43BC-A7C2-8337E0790CCDQ36331321-754A0797-E9BB-428C-B52A-0C285CBB250AQ37545245-14FF0FB2-216F-4225-AFBF-1415B3301803Q37806321-97D49BCD-3545-42CF-8DB3-FD5AA90590A8Q38193826-BB14B85B-2E5E-4332-9DDD-ADE84752BBA9Q39256722-5C71F0CC-4C28-4A30-BB02-0C105BA25F69Q42196444-F3198D9F-6C2F-43F8-AF98-8DED8843D486Q43245686-0C884030-ADFD-4BD6-9DD3-036964718F4FQ47547148-B69BA019-D886-4FFD-85E4-D2AF22230707Q50674112-2BDC5DA5-F656-4303-873F-94F6673FFFCAQ55208760-FB05F470-08C5-4B41-9117-AB2347739411Q55427105-ABF0C1C1-CD81-4EF0-8FD8-FC834221C7C6
P2860
Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Intravitreal bevacizumab (Avas ...... tinopathy: 6-months follow-up.
@en
type
label
Intravitreal bevacizumab (Avas ...... tinopathy: 6-months follow-up.
@en
prefLabel
Intravitreal bevacizumab (Avas ...... tinopathy: 6-months follow-up.
@en
P2093
P2860
P356
P1433
P1476
Intravitreal bevacizumab (Avas ...... tinopathy: 6-months follow-up.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.EYE.6702980
P577
2007-09-21T00:00:00Z